Interestingly, a recent study reported that the GLP-1R agonist liraglutide ameliorates NAFLD in diabetic mice via the IRS2/PI3K/AKT signaling pathways [74]. The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.